|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
"Exosomal onco-miRs" such as miR-223-5p, miR-223-3p, miR-483-5p, miR-409-3p, miR-196b-5p, miR-192-5p, miR-146a-5p, and miR-126-5p have been identified as part of exosomal cargo being overexpressed in corresponding tumor compared to normal.
|
25631748 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor xenograft model in nude mice was utilized to evaluate the influence of miR-126 on tumor growth.
|
27611944 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9.
|
22064652 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MiR126 affects mitochondrial energy metabolism, resulting in MM tumor suppression.
|
24444362 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-126 (miR-126) has been reported to be a tumor suppressor that targets CXCR4 in colorectal cancer (CRC) cells.
|
24532280 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-126 modulates the tumor microenvironment by targeting calmodulin-regulated spectrin-associated protein 1 (Camsap1).
|
24603804 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MiR-126 was reported to act as a tumor suppressor by targeting the Crk gene, or as an oncogene by targeting the SOX2 gene in gastric cancer.
|
24969300 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-126(miR-126) has been shown to be frequently down-regulated in a variety of malignancies and act as a potential tumor suppressor.
|
25551621 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
microRNA-126 (miR-126) has been reported to play tumor suppressor roles in various types of cancers.
|
26239517 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-126 (miR-126) is significantly downregulated in a number of tumor types and is commonly identified as a tumor suppressor in digestive system cancers (DSCs). miR-126 downregulates various oncogenes, including disintegrin and metalloproteinase domain-containing protein 9, v-crk sarcoma virus CT10 oncogene homolog and phosphoinositide-3-kinase regulatory subunit 2.
|
30655735 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MiR-126-3p is commonly down-regulated and exerts tumor-suppressive roles in kinds of human cancers, including GBM.
|
30980849 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-126 functions as a tumor suppressor in cervical cancer cells in vitro, which inhibits the proliferation, migration and invasion by suppressing MMP2, MMP9 expression and inactivating JAK2/STAT3 signaling pathway through targeting ZEB1, suggesting that miR-126 might be a novel potential target for the diagnosis and treatment of patients with cervical cancer.
|
31007650 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A reduced miR-126 expression and an elevated Crk protein expression, alone or in combination, statistically correlated with aggressive clinicopathological characteristics, such as larger tumor size, deeper local invasion, more lymph node metastasis, advanced TNM stage, and poorer prognosis.
|
29171987 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A reduced serum miR-126 level statistically correlated with aggressive clinicopathological characteristics, such as larger tumor size, deeper local invasion, more lymph node metastasis, advanced TNM stage, and poorer prognosis.
|
29562500 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A reduced tissue miR-126 level statistically correlated with aggressive clinicopathological characteristics, including larger tumor size, deeper local invasion, and poorer prognosis.
|
30248047 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer.
|
19375957 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additional, high miR-126 expression reduced the tumor growth in vivo.
|
30315225 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, it was hypothesized that miR-126, described as a tumor suppressor in ESCC, may act at least in part via its inhibition of PTPN9 at the post-transcriptional level.
|
28789358 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After 6 weeks, the tumor volume in the miR-126 inhibitor group was significantly increased, while that in the MTCP1 siRNA group was significantly decreased.
|
30233082 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All these results revealed that miR-126 may have a tumor suppressor function in lung cancer cells and could be a promising treatment in anticancer therapy.
|
19223090 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Among the microRNAs (miRNAs) that control different cellular processes, miR-24, miR-126 and miR-365 were shown to regulate cell cycle progression and apoptosis in various types of tumors.
|
24153013 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An increase in miR-200b was correlated with high-risk tumors (p = 0.01) while miR-126 overexpression was associated with Fuhrman's low grade (p = 0.03).
|
29202733 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, the present study revealed that miR‑126‑3p plays a role as a tumor suppressor in regulating TNBC cell activities by targeting RGS3, indicating that the miR‑126‑3p/RGS3 axis may be a potential treatment target.
|
31364749 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, these results demonstrated that miR-126 acts as a tumor suppressor by inactivating RhoA signaling via CXCR4 in colon cancer.
|
27517626 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consistently, MIR126-expressing MM cells injected into immunocompromised mice failed to progress beyond the initial stage of tumor formation, showing that increased autophagy has a protective role in MM.
|
27119351 |
2016 |